Tumor development in a patient with S ézary syndrome treated with pembrolizumab

An 80-year-old Caucasian male previously diagnosed with S ézary syndrome (SS) in 2009 presented to our multidisciplinary cutaneous lymphoma clinic for a second opinion. He had failed therapies with topical steroids, narrow-band UVB, oral bexarotene, interferon-α, vorinostat, and photopheresis. In October 2017, his outside oncologist added pembrolizumab ( PEM) to his monthly photopheresis. After six cycles of PEM, he developed 25-lb weight loss, lymphadenopathy, and skin lesions. On exam, he had erythematous patches over 72.5% body surface area (BSA) and violaceous firm nodules over 4.8% BSA.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research